Page 1

01 02 03 04 INTERIM REPORT Q2 2021 | ACTIVE BIOTECH AB ● SECOND QUARTER IN BRIEF Active Biotech and NeoTX announce FDA clearance of IND for phase II clinical trial of naptumomab ● EVENTS AFTER THE END OF THE PERIOD Active Biotech provided status update on the progress in its clinical naptumomab project Active Biotech's partner NeoTX hosted KOL webinar on overcoming checkpoint inhibitor resistance , featuring combination with naptumomab as one approach ● Active Biotech Active FINANCIAL SUMMARY Good progress in the projects towards important clinical events SEK M Net sales Operating profit / loss Profit / loss after tax Earnings per share ( SEK ) Cash and cash equivalents ( at close of period ) The report is also available at www.activebiotech.com 2021 Apr - Jun -12.6 -12.6 -0.06 2020 -10.1 -9.8 -0.06 2021 Jan - Jun -22.4 -22.4 -0.11 78.5 2020 0.5 -19.9 -19.9 -0.12 38.2 Full - year 2020 6.7 -32.3 -32.2 -0.19 26.2 Active Biotech is obligated to make public the information contained in this report pursuant to the EU Market Abuse Regulation and the Swedish Securities Market Act . This information was provided to the media , through the agency of the contact person set out above , for publication on August 5 , 2021 , at 08.30 a.m. CET . Active Biotech AB ( Corp. reg . no . 556223-9227 ) / Scheelevägen 22 , SE - 223 63 Lund / +46 ( 0 ) 46 19 20 00 / www.activebiotech.com Helén Tuvesson , CEO : +46 ( 0 ) 46 19 21 56 / Hans Kolam , CFO : +46 ( 0 ) 46 19 20 44